Philip Huxley
Algemeen Directeur bij Ducentis BioTherapeutics Ltd.
Profiel
Philip Huxley has founded Ducentis BioTherapeutics Ltd.
in 2014, where he currently holds the title of Chief Executive Officer.
He has held former positions as Director-Drug Discovery Division at Galapagos Genomics NV, Head-Molecular Design at Ligand UK Ltd., Chief Technology Officer at Prexa Pharmaceuticals, Inc., Principal at Novartis AG, Head-Drug Discovery at Avidex Ltd., and Principal at Spear Therapeutics Ltd.
Dr. Huxley received his undergraduate degree from the University of Aberdeen and his doctorate degree from the University of Sussex.
Actieve functies van Philip Huxley
Bedrijven | Functie | Begin |
---|---|---|
Ducentis BioTherapeutics Ltd.
Ducentis BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Ducentis Biotherapeutics Ltd. develops novel therapies for inflammation and autoimmune disease. The company was founded by Rebecca Ashfield, David Blackbourn and Philip Huxley in March 2015 and is headquartered in Witney, the United Kingdom. | Algemeen Directeur | 12-11-2014 |
Eerdere bekende functies van Philip Huxley
Bedrijven | Functie | Einde |
---|---|---|
Spear Therapeutics Ltd.
Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Corporate Officer/Principal | - |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Corporate Officer/Principal | - |
VERNALIS | Corporate Officer/Principal | - |
NOVARTIS AG | Corporate Officer/Principal | - |
Opleiding van Philip Huxley
University of Aberdeen | Undergraduate Degree |
University of Sussex | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NOVARTIS AG | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Prexa Pharmaceuticals, Inc.
Prexa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prexa Pharmaceuticals, Inc. developed oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It engaged in developing small molecules designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression, and Parkinson's disease. The company was founded in 2006 and was headquartered in Boston, MA. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Spear Therapeutics Ltd.
Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Health Technology |
Ducentis BioTherapeutics Ltd.
Ducentis BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Ducentis Biotherapeutics Ltd. develops novel therapies for inflammation and autoimmune disease. The company was founded by Rebecca Ashfield, David Blackbourn and Philip Huxley in March 2015 and is headquartered in Witney, the United Kingdom. | Health Technology |